# Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma

> **NCT02086552** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 28 (actual)

## Conditions studied

- Recurrent Plasma Cell Myeloma
- Refractory Plasma Cell Myeloma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Lenalidomide
- **DRUG:** Sonidegib

## Key facts

- **NCT ID:** NCT02086552
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01-17
- **Primary completion:** 2018-01-15
- **Final completion:** 2021-08-13
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2021-12-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02086552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02086552, "Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02086552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*